Lernidum

Lercanidipine Hydrochloride, the active ingredient in Lernidum, is a calcium channel blocker presented as an oral tablet for oral use. It is prescribed to lower elevated blood pressure in adults with hypertension and to reduce associated cardiovascular risk.

GNH USA supplies Lernidum as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lernidum (Lercanidipine Hydrochloride) belongs to the calcium channel blocker class and is used to manage high blood pressure. - Hypertension: lowers elevated blood pressure and reduces cardiovascular risk in adults.

Lernidum may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Headache: mild to moderate pain often occurring after the first dose. - Flushing: transient warmth and redness of the face or neck. - Peripheral edema: swelling of the ankles or lower legs. - Dizziness: sensation of light‑headedness, especially when standing quickly.

Serious or Rare Side Effects: - Angioedema: swelling of the face, lips, tongue, or throat that may compromise breathing. - Severe hypotension: marked drop in blood pressure causing fainting or shock. - Hepatic dysfunction: abnormal liver enzyme elevations indicating possible liver injury.

Before initiating therapy, clinicians should consider several safety factors. - Monitor blood pressure: regular measurements to assess therapeutic response. - Avoid abrupt discontinuation: taper the dose to prevent rebound hypertension. - Caution in hepatic impairment: dose adjustment may be required. - Use with caution in elderly patients: increased sensitivity to hypotensive effects. - Review concomitant medications: assess for potential drug interactions. - Store at room temperature: keep in the original container, protect from moisture and light.

Lernidum can interact with other medicines, altering its effectiveness or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase plasma concentrations. - Co‑administration with other antihypertensives that cause additive hypotension. - Grapefruit juice: can raise drug exposure and risk of adverse effects.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce therapeutic effect. - Non‑dihydropyridine calcium channel blockers: may affect cardiac conduction. - Diuretics: may enhance the antihypertensive response and increase risk of electrolyte imbalance.